But the healthcare system in the US still struggles to provide adequate care for those with serious mental illness
Care home costs have been rising steeply
More trials urged as part of effort to slow cognitive declines with existing medicines
Nice’s ruling on lecanemab demonstrates the lack of readiness to roll out new treatments in the UK
Spending watchdog declines to give green light to lecanemab for patients in England
The Food and Drug Administration’s rejection of MDMA-assisted therapy is a missed opportunity
Sports stars open up about the pressures they face — and the ‘decompression’ after high-profile events
‘Vampire Therapist’, where you play a bloodsucking counsellor, is one of a wave of titles putting psychology at the centre
Huge rise in prescriptions for women aged 25 to 34 in England driven by social media highlighting symptoms
Reducing 14 ‘modifiable’ risks can prevent or delay cognitive disorder, report says
Dan Taberski looks at the events of 2011 in a New York town when a group of girls all came down with Tourette’s-like symptoms
Eisai and Biogen face uphill battle to win EU approval for Leqembi after committee’s ruling
GSK’s Shingrix is latest drug to show potential for targeting previously untreatable brain disorders
It took a silent retreat to reboot my relationship with smartphones and social media
The dopamine hit of smartphones, described as the modern-day hypodermic needle, is not the same as switching off
Those of us who fall ill as soon as we stop work may need to rethink our approach to life
Inside the historic trial that convicted the parents of a school shooter
Poll finds rise from 6% to 9% of central bank’s workers reporting suicidal thoughts
Decision to associate charity with a cure turned it into Europe’s biggest funder of dementia research
New drug Kisunla will be 20% more than rival as drugmaker claims it requires fewer treatments
Employers are often less flexible with staff who need to care for older children
Oral formulation offers prospect of cheaper and more convenient access to drug, research suggests
Workers still fear discrimination despite years of raising awareness — do companies need to go further?
Independent experts conclude unanimously that the experimental treatment is effective
Solving the issue needs to be a bipartisan effort
